Skip to main content Skip to office menu Skip to footer
Capital IconMinnesota Legislature

Office of the Revisor of Statutes

HF 2275

Introduction - 94th Legislature (2025 - 2026)

Posted on 03/13/2025 03:01 p.m.

KEY: stricken = removed, old language.
underscored = added, new language.

Bill Text Versions

Engrossments
Introduction
PDF
Posted on 03/13/2025
Line numbers 1.1 1.2 1.3 1.4
1.5 1.6 1.7 1.8 1.9 1.10 1.11 1.12 1.13 1.14 1.15 1.16 1.17 1.18 1.19 1.20

A bill for an act
relating to health; modifying insulin manufacturer registration fee provisions;
amending Minnesota Statutes 2024, section 151.741, subdivision 2.

BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF MINNESOTA:

Section 1.

Minnesota Statutes 2024, section 151.741, subdivision 2, is amended to read:


Subd. 2.

Assessment of registration fee.

(a) The board shall assess each manufacturer
an annual registration fee of $100,000, except as provided in paragraph (b). The board shall
notify each manufacturer of this requirement beginning November 1, 2024, and each
November 1 thereafter.new text begin The commissioner of health shall provide technical assistance to
the board using available data sources, including but not limited to data collected under
section 62U.04.
new text end

(b) A manufacturer may request an exemption from the annual registration fee. The
board shall exempt a manufacturer from the annual registration fee if the deleted text begin manufacturer can
demonstrate to the board, in the form and manner specified by the board, that gross revenue
deleted text end new text begin
total wholesale acquisition cost
new text end from deleted text begin sales ofdeleted text end new text begin dispensing claims within or into Minnesota
for
new text end prescription insulin produced by that manufacturer deleted text begin and sold or delivered within or into
Minnesota
deleted text end was less than five percent of the total deleted text begin gross revenuedeleted text end new text begin wholesale acquisition costnew text end
from deleted text begin sales of prescription insulin produced by all manufacturers and sold or delivered within
or into Minnesota
deleted text end new text begin dispensing claims of prescription insulin products by all manufacturers
within or into Minnesota
new text end in the previous calendar year.